# Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Biotech Firm Surges with 200% Upside Potential

- Link: https://www.directorstalkinterviews.com/soleno-therapeutics-inc-slno-stock-analysis-biotech-firm-surges-with-200-upside-potential/4121240103
- Published: 2026-02-16T11:36:23+00:00
- Author: Madison Wilson

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company
focused on developing therapeutics for rare diseases, is capturing investor attention
with a remarkable potential upside of 200.55%. This Redwood City-based company, 
with a market capitalization of $2 billion, is poised at the intersection of innovation
and growth within the healthcare sector, particularly in the biotechnology industry.

**Current Market Position**

As of the latest trading session, Soleno Therapeutics’ share price stands at $37.24,
experiencing a modest decline of 0.04%. The 52-week price range reveals a volatile
year for the stock, fluctuating between $37.24 and $88.49. While the current price
hovers at the lower end of this spectrum, the consensus among analysts suggests 
significant room for growth.

**Analyst Ratings and Potential Upside**

The company enjoys a strong endorsement from Wall Street, with 13 buy ratings and
no hold or sell ratings. The analysts’ average target price is set at $111.92, with
a price range extending from $60.00 to $145.00. This robust confidence underscores
the company’s promising future, driven by its lead product candidate, Diazoxide 
Choline Extended-Release tablets, which are in Phase III clinical trials for Prader-
Willi Syndrome.

**Valuation and Financial Performance**

Despite the excitement surrounding its potential, Soleno Therapeutics presents a
challenging financial picture, typical for a company in its developmental stage.
Key valuation metrics such as the P/E ratio, PEG ratio, and price-to-book ratio 
are currently not applicable, reflecting the company’s focus on research and development
rather than immediate profitability.

The company’s performance metrics further reveal the typical financial strains of
a clinical-stage firm, with a negative earnings per share (EPS) of -1.75 and a return
on equity of -20.66%. Furthermore, its free cash flow stands at -$5,702,500, indicating
significant cash burn as it advances its clinical trials.

**Technical Indicators**

From a technical perspective, Soleno’s stock is trading below its 50-day and 200-
day moving averages of $45.12 and $63.85, respectively. The Relative Strength Index(
RSI) of 33.90 suggests that the stock is approaching oversold conditions, which 
may appeal to value investors seeking entry points. However, the negative MACD of-
1.68 and signal line of -1.51 highlight ongoing bearish momentum.

**Investment Outlook**

Soleno Therapeutics presents a compelling opportunity for investors with a high-
risk tolerance and a keen interest in the biotechnology sector. The company’s advancements
in treating rare diseases and the potential market approval of its lead product 
could serve as significant catalysts for stock appreciation. However, the inherent
risks associated with clinical trials and regulatory approvals should not be overlooked.

For investors, the allure of a 200% upside is balanced by the volatility typical
of biotech stocks in the clinical phase. Those considering an investment in SLNO
should keep a close watch on trial results and regulatory news, as these will play
critical roles in shaping the company’s trajectory and, by extension, its stock 
performance.

Share on: